The US hedge fund
industry strongly supports the final EU Regulation on OTC derivative
transactions, central counterparties and trade repositories. The European Market Infrastructure Regulation (EMIR) is an
important step towards central clearing of OTC derivatives, increasing market
transparency and reducing systemic risk.
In particular, the Managed Funds Association applauds the mandatory
inclusion of client representatives on central counterparty risk committees and the requirement that central
counterparties offer both omnibus and individual client collateral segregation
arrangements.
In this spirit, the MFA
commented on the proposed standards of the European Securities and Markets
Authority (ESMA) implementing EMIR in an effort to assist ESMA in finalizing the
standards in a way that will enhance the governance of central counterparties,
increase clearing certainty and the protections and information provided to
clients, and ensure consistent and effective global regulation of the OTC
derivatives markets. In a letter to ESMA, the hedge fund group said that
clients should be represented on the governing bodies of central
counterparties. Thus, the MFA supports
the ESMA proposal requiring central counterparty governance arrangements to
include processes for ensuring accountability to stakeholders. In addition, the
MFA urged ESMA to include anti-circumvention measures in the final standards.
These measures would obligate
the central counterparty governing bodies to refrain from making decisions
regarding their governance and operations with the intention of circumventing
any EMIR client protection or
transparency requirement, and to actively consider the interests of all
stakeholders, including clients, in providing clearing services and managing
the central counterparty. The final standards should also guard against circumvention of the EMIR transparency
requirements by requiring central counterparties to give client representatives
and independent directors rights to attend all meetings of all central
counterparty governing bodies, including subcommittees, if such meetings deal
with matters that directly affect clients’ interests, such as changes to margin
valuation
Models.
The MFA also asked that central
counterparties be required to disclose the identity of the members of its board,
of the risk committee and other significant board subcommittees. ESMA should also mandate disclosure of central
counterparty ownership interests held by central counterparty directors and
senior management. Mandating this level of transparency would not only expose
any conflicts of interest, noted the MFA, but it would also ensure consistent
global derivatives regulation since it would be consistent with proposed SEC
and CFTC requirements.
The hedge fund association
commended ESMA for providing a framework for sound portfolio margining
practices that permit offsets across correlated financial instruments,
with a single default fund covering all
financial instruments under the same portfolio
margining arrangements. The association urged ESMA to allow give
counterparty risk managers and risk committees the flexibility to determine the
permitted parameters of portfolio margining models for different products and
asset classes, including offsets and risk correlation levels, subject to regulatory
oversight. The MFA reasoned that risk managers and risk committees are in the
best position to determine, and adjust as market conditions evolve, the proper
level of negative correlation and offset for different financial instruments,
subject to regulatory supervision.
Cross-Border Application of EMIR
ESMA will deal with the
extraterritorial application of EMIR to non-EU counterparties at a later time.
The MFA urged ESMA to publish a consultation as soon as possible addressing the
application of EMIR to transactions between US non-EU counterparties that have
a direct, substantial and foreseeable effect within the EU. Due to the
cross-border nature of derivatives markets, the MFA urged ESMA to draft standards
setting out clearly and precisely the circumstances in which ESMA considers an
OTC derivative contract to have a direct, substantial and foreseeable effect
within the EU; and that it is necessary or appropriate to apply the clearing
and risk mitigation obligations to contracts between US and other third-country
counterparties in order to prevent the evasion of the requirements under EMIR.
Particularly,
ESMA should consider a number of factors in drafting the standards, said the
MFA, including the domicile of the hedge fund and the fund manager, the
domicile of the counterparty, and the location of the market. The standards
should clarify that transactions between two US or other third-country entities
are not within the scope of EMIR simply because there is an EU reference
security or other EU underlying instrument.
However, if ESMA should
subject a contract between two US or other third-country parties to EMIR’s clearing
obligation due to the contract having an EU reference security or other underlying,
the hedge fund group asked that the standards provide that it can be deemed to
have a direct, substantial and foreseeable effect within the EU only if it
satisfies three specific factors.
The first factor is that, for
derivatives referencing a security, such as equity derivatives and credit default
swaps, the reference entity must be domiciled and have its principal place of
business in the EU; and for foreign exchange derivatives, the Euro or another
currency of an EU member state must be one of the relevant currencies. The
second factor is that the settlement currency of the contract must be in Euros
or the currency of another EU member state. The third factor is that the
notional amount of the contract must be substantial.